SCHEMBL22270414

SCHEMBL22270414

CC(C(=O)Nc1ccc(Cl)cc1)C1C[C@H]2CC(c3ccnc4ccc(F)cc34)C[C@H]2C1

nearest known ligand 0.80

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
▸ IDO1 P14902 20/20 0.80
▸ CYP2C9 P11712 5/20 0.80
▸ CYP2C8 P10632 3/20 0.80
▸ TDO2 P48775 2/20 0.80
▸ CYP3A4 P08684 1/20 0.80
▸ KCNH2 Q12809 1/20 0.80
▸ CHRNA1 P02708 1/20 0.56
▸ CYP2C19 P33261 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22270382 1.00 IDO1 (0.80) IDO1CYP2C9CYP2C8TDO2CYP3A4
SCHEMBL22387220 1.00 IDO1 (0.80) IDO1CYP2C9CYP2C8TDO2CYP3A4
SCHEMBL22270954 1.00 IDO1 (0.80) IDO1CYP2C9CYP2C8TDO2CYP3A4
SCHEMBL22387338 1.00 IDO1 (0.80) IDO1CYP2C9CYP2C8TDO2CYP3A4
SCHEMBL22270899 1.00 IDO1 (0.80) IDO1CYP2C9CYP2C8TDO2CYP3A4
SCHEMBL22270952 1.00 IDO1 (0.80) IDO1CYP2C9CYP2C8TDO2CYP3A4
SCHEMBL22387339 1.00 IDO1 (0.80) IDO1CYP2C9CYP2C8TDO2CYP3A4
SCHEMBL21583813 1.00 IDO1 (0.80) IDO1CYP2C9CYP2C8TDO2CYP3A4
SCHEMBL22270953 1.00 IDO1 (0.80) IDO1CYP2C9CYP2C8TDO2CYP3A4
SCHEMBL28335279 1.00 IDO1 (0.80) IDO1CYP2C9CYP2C8TDO2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3686196-A1 POLYCYCLIC COMPOUND ACTING AS IDO INHIBITOR AND/OR IDO-HDAC DUAL INHIBITOR Hangzhou Innogate Pharma Co., Ltd. (CN) 2020-07-29 — — EP disclosed
CN-110540521-A Octahydro pentalene compound, preparation method and application thereof in medicine and pharmacology BEIJING INNOCARE PHARMA TECH CO LTD 2019-12-06 — — CN disclosed
Send feedback